ClinConnect ClinConnect Logo
Search / Trial NCT06146725

The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

Launched by JASPER GERRITSEN · Nov 18, 2023

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

Resection Biopsy Survival Quality Of Life

ClinConnect Summary

The RESBIOP study is researching the best surgical approach for older patients (70 years and older) or those with limited health status who are diagnosed with high-grade gliomas, a type of aggressive brain tumor. The main goal is to compare two methods: removing as much of the tumor as possible (resection) versus taking a small sample of the tumor (biopsy). By looking at how these methods affect survival, quality of life, and the chance of receiving additional treatments like chemotherapy or radiation, the study hopes to provide clearer guidance for doctors and patients.

To participate in this study, individuals must be between 18 and 90 years old and have been diagnosed with a high-grade glioma based on MRI scans. Participants will be randomly assigned to either the resection or biopsy group and will be followed for one year after their procedure. Throughout the study, researchers will monitor participants’ health, quality of life, and any side effects experienced. This study is currently recruiting participants and will last a total of five years.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age ≥18 years and ≤90 years
  • 2. Tumor diagnosed as HGG (WHO grade III/IV) on MRI as assessed by the neurosurgeon
  • 3. Written informed consent
  • Exclusion Criteria:
  • 1. Tumors of the cerebellum, brainstem or midline
  • 2. Medical reasons precluding MRI (e.g. pacemaker)
  • 3. Inability to give written informed consent
  • 4. Secondary high-grade glioma due to malignant transformation from low-grade glioma
  • 5. Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin

About Jasper Gerritsen

Jasper Gerritsen is a dedicated clinical trial sponsor committed to advancing medical research through innovative and ethical study design. With a focus on enhancing patient outcomes, Jasper Gerritsen collaborates with leading healthcare professionals and institutions to conduct rigorous clinical trials across various therapeutic areas. The organization prioritizes transparency, compliance, and the highest standards of scientific integrity, ensuring that all trials are conducted with the utmost care for participant safety and data quality. By leveraging cutting-edge methodologies and fostering strong partnerships, Jasper Gerritsen aims to contribute significantly to the development of new therapies that address unmet medical needs.

Locations

Boston, Massachusetts, United States

San Francisco, California, United States

Leuven, , Belgium

Heidelberg, , Germany

Bern, , Switzerland

The Hague, , Netherlands

Rotterdam, Zuid Holland, Netherlands

Munich, Bavaria, Germany

Patients applied

0 patients applied

Trial Officials

Jasper Gerritsen, MD PhD

Principal Investigator

Erasmus Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported